<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Clinical Neurosciences</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/7BB1FCBA-BC86-4DE3-9404-E41BB4849178"><gtr:id>7BB1FCBA-BC86-4DE3-9404-E41BB4849178</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Beeson</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G117%2F490"><gtr:id>DD235875-8977-4CC4-A36B-B7B5A362EA0C</gtr:id><gtr:title>Disease mechanisms and RNA-based therapies for pathogenic mutations at the neuromuscular synapse</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G117/490</gtr:grantReference><gtr:abstractText>Nerves communicate through the transfer of electrical signals, achieved largely by opening and closing ion channels in their cell surface at specialised sites called synapses. Recent research into inherited brain diseases suggests that defects in the opening and closing of ion channels or in their precise positioning may contribute to some of the more common brain disorders such a migraine and epilepsy. We believe an understanding of how ion channels malfunction at synaptics sites will help both in finding the causes of many neurological disorders and in devising therapies. We study inherited diseases called congenital myasthenic syndromes that cause severe disability in children and adults and affect ion channels, called acetylcholine receptors, located at the connection between nerves and muscles. Inherited mutations affecting these receptors in different ways, causing disease that may or may not be treatable. Understanding how these mutations cause disease enables us to give patients correct treatments and counselling, and provides the knowledge base required for exploring new therapies. In this project we will use fluorescently-labelled receptors to visualise how the mutations are causing disease and we will explore new methods of treatments that should prevent the production of the harmful disease-causing proteins .</gtr:abstractText><gtr:technicalSummary>Congenetial myasthenic syndromes (CMS) stem from genetic defects that afect transmission of information from nerves to muscles at the neuromuscular junction (NMJ) and result in fatiguable muscle weakness. They comprise a disabling - and sometimes potentially lethal - set of disorders with subtly different clincal features that arise from different underlying molecular mechanisms. An understanding of the different disease mechanisms enables appropriate treatments to be given to patients, will facilitate investigations of more common CNS disorders, and provides model examples of synaptic dysfunction that may be used to evaluate new treatment strategies such as RNA -based gene therapy. Gene silencing or gene repair that targets mRNA is a rapidly evolving area of biology that has been given a powerful boost by the discovery of RNA interference (RNAi) as a mechanism for turning off gene expression. Acetylcholine receptors (AChR) are the ion channels that receive the signal for muscle contraction. The majority of mutations in CMS patients are in the AChR, but recently we have detected a series of mutations in another protein, rapsyn, in which clusters and anchors AChR at the NMJ. 

The objective of this proposal is twofold i) to set up disease models of rapsyn mutations to investiate the molecular mechanisums that underlie the muscle weakness, and ii) to explore the potential of RNAi and catalytic nucleic acids for allele-specific gene silencing and gene repair in an inherited neurological disorder. 

We have recently shown that green flourescent protein can be integrated into human AChR without affecting its function. We shall use this new experimental tool in a combination of microscopic and genetic techniques to determine if rapsyn mutations affect the stability of AChR?s in the surface membrane or the process of insertion into the membrane, and to determine effects on the fetal form of AChR that cause deformities at birth. Previously we have characterised AChR mations that have dominant excitotoxic functional effects or are null mutations. We will compare the ability of RNAi, DNAzymes and hammerhead ribozymes to give allele-specific down regulation of mutant-AChR mRNA, and investigate repair of mutant e-subunit mRNA by group I intron ribozymes . Efficacy will be established inHEK 293 cells, muscle cell lines, mutant muscle cell lines from patients, and in vivo models. We will continue to screen CMS patients for mutations in new candidate genes by PCR and automated sequence analysis. Effects on AChR function will be assessed using biochmical and electrophysiological techniques.</gtr:technicalSummary><gtr:fund><gtr:end>2008-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2003-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1046208</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Physiology, Anatomy and Genetics</gtr:department><gtr:description>OXION Wellcome Trust ion channels initative</gtr:description><gtr:id>37B4CAF8-38DB-41F8-BF31-FD68A44D5065</gtr:id><gtr:impact>A series of papers involve members of the OXION consortium.</gtr:impact><gtr:outcomeId>AkR2Y2KhkeS-1</gtr:outcomeId><gtr:partnerContribution>Provided a 3 year fully-funded post-doctoral research fellow</gtr:partnerContribution><gtr:piContribution>I am on OXION management committee, and collaborated in writing grant application. As part of the consortium my group was chosen by one of the research fellows.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Oxford science week</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>6F22DA4C-F44C-4624-8550-E0929FA5D3F0</gtr:id><gtr:impact>Open lecture to the public

Useful conversations</gtr:impact><gtr:outcomeId>2B6D0989C0E</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lectures to patient groups</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1E8511BE-00F5-4A10-80F1-F20586F704B6</gtr:id><gtr:impact>Regularly give talks to small patient groups and parents who have an obvious interest in inherited myasthenic disorders

Useful patient researcher contact.</gtr:impact><gtr:outcomeId>290D2A0AFEA</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Congenital myasthenic syndrome open day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1AB7DF1D-3FB3-427C-9245-A43C3988A28F</gtr:id><gtr:impact>Patient day. Patients are given a series of lectures on scientific research updates, and then in the afternoon there are a series of workshops for particular patient groups where needs that have been identified or areas of special interest are addressed. Typically this might involve treatments, exercise, benefits, future therapy updates.

Patients and researchers are both enthused about the research effort</gtr:impact><gtr:outcomeId>885B5E80795</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:url>http://www.ouh.nhs.uk/services/referrals/neurosciences/myasthenia.aspx</gtr:url><gtr:year>2006,2008,2010,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Work experience</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>94E6E2AD-7FF5-4787-8440-856F6C340F90</gtr:id><gtr:impact>Individual students spend a week in the laboratory learning about scientific research.

School comes back each year requesting further pupil experience.</gtr:impact><gtr:outcomeId>FXxCfJfBJfB</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2008,2009,2010,2011,2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1482000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Programme Grant</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G0701521</gtr:fundingRef><gtr:id>E9FDF88C-92D9-4D11-A31D-93F79823F69D</gtr:id><gtr:outcomeId>cDXrusnGAbb0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>We demonstrated this commonly available drug has a remarkable beneficial effect for patients with DOK7 CMS.</gtr:description><gtr:id>C23622A3-D4F9-47C3-8EBA-F41ED127B20A</gtr:id><gtr:impact>Use of ephedrine in DOK7 CMS patients results in a dramatic improvement in disability scores. For example patients who were in wheel chairs are now often able to run.

Ephedrine and salbutamol (which acts in a similar way) are now therapies of choice for DOK7 CMS</gtr:impact><gtr:outcomeId>G5FqGAjr2XV</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>ephedrine</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2006</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>cDNA clones expressing CHRNA, CHRNB, CHRNG, CHRND, CHRNE, RAPSN, AGRN, DOK7,</gtr:description><gtr:id>CD78BAB3-456C-45DD-8A0A-556DEB53D436</gtr:id><gtr:impact>Provided expression constructs to numerous laboratories throughout the world for studies of the neuromuscular junction, both pre and post 2006.</gtr:impact><gtr:outcomeId>ZVfrChBoUDd</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Expression plasmids</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Mouse model of AChR deficiency syndrome</gtr:description><gtr:id>B895518C-82E6-4100-BCB8-796E3A29290A</gtr:id><gtr:impact>Cossins et al., 2004.
Used to establish optimum therapeutic strategies for difficult to treat patients.</gtr:impact><gtr:outcomeId>RQh9kmc5Xj8</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Model of AChR deficiency syndrome</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Cell lines from patients with congenital myasthenic syndromes</gtr:description><gtr:id>92C5C256-B49E-4E65-9E20-0B475356F98A</gtr:id><gtr:impact>Used in determining underlying disease mechanism and in determining if DNA variants are pathogenic</gtr:impact><gtr:outcomeId>q5Nkpi81Dxt</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>cell line</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>955A7382-7EF4-40C3-8FE8-789454D8CC22</gtr:id><gtr:title>Rhabdomyosarcoma lysis by T cells expressing a human autoantibody-based chimeric receptor targeting the fetal acetylcholine receptor.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef44751943f93ad4dcde5a0efad81e55"><gtr:id>ef44751943f93ad4dcde5a0efad81e55</gtr:id><gtr:otherNames>Gattenl?hner S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>8E673F50BD7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11340968-A2E9-44C7-BAAF-CCB9C0B3FCE6</gtr:id><gtr:title>A mouse model of AChR deficiency syndrome with a phenotype reflecting the human condition.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51cba051719f81ef2c20624dca20d9fa"><gtr:id>51cba051719f81ef2c20624dca20d9fa</gtr:id><gtr:otherNames>Cossins J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_13880_10_15471888</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>75AC2A59-F5B5-45CD-8A79-4CC222CB6E98</gtr:id><gtr:title>A mouse model of the slow channel myasthenic syndrome: Neuromuscular physiology and effects of ephedrine treatment.</gtr:title><gtr:parentPublicationTitle>Experimental neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7526f3636d632aaa7edc6a8cdb921b5b"><gtr:id>7526f3636d632aaa7edc6a8cdb921b5b</gtr:id><gtr:otherNames>Webster RG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0014-4886</gtr:issn><gtr:outcomeId>pm_13880_20_23797154</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A069DC72-A870-4A53-B30C-FA5BF01BD28E</gtr:id><gtr:title>Mutations causing DOK7 congenital myasthenia ablate functional motifs in Dok-7.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/05223636bcfe92d6327c2b5d268d1c13"><gtr:id>05223636bcfe92d6327c2b5d268d1c13</gtr:id><gtr:otherNames>Hamuro J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>D37172D6FB5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5AEDE5AD-145A-4107-9F4B-C365B4543307</gtr:id><gtr:title>Effect of sera from AChR-antibody negative myasthenia gravis patients on AChR and MuSK in cell cultures.</gtr:title><gtr:parentPublicationTitle>Journal of neuroimmunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8adbead5ccc9d4b4e37661f6297d2147"><gtr:id>8adbead5ccc9d4b4e37661f6297d2147</gtr:id><gtr:otherNames>Farrugia ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0165-5728</gtr:issn><gtr:outcomeId>0C9BF638F75</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9CFFCAB-87B1-462E-8FB9-3B638AA6A76E</gtr:id><gtr:title>Isolation of potent human Fab fragments against a novel highly immunogenic region on human muscle acetylcholine receptor which protect the receptor from myasthenic autoantibodies.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/209f9f57fdb49e0c653d2d02bbedd434"><gtr:id>209f9f57fdb49e0c653d2d02bbedd434</gtr:id><gtr:otherNames>Fostieri E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>pm_13880_10_15627975</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>866C4120-1764-496A-8A86-56C1DB8EDE1E</gtr:id><gtr:title>Clinical features of the DOK7 neuromuscular junction synaptopathy.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cad527b64016a7b9db06e95b702905ac"><gtr:id>cad527b64016a7b9db06e95b702905ac</gtr:id><gtr:otherNames>Palace J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>016093011BB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD77280A-73BC-4F23-B543-5725A496C76F</gtr:id><gtr:title>Mutation in the AChR ion channel gate underlies a fast channel congenital myasthenic syndrome.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f022b8687d82dc8df9d836a488d074d"><gtr:id>8f022b8687d82dc8df9d836a488d074d</gtr:id><gtr:otherNames>Webster R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>pm_13880_10_15079006</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2EA1D2A1-B2B3-420A-8E39-69999F3C9461</gtr:id><gtr:title>Hairpin DNAzymes: a new tool for efficient cellular gene silencing.</gtr:title><gtr:parentPublicationTitle>The journal of gene medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ff6818641f1c9492b88729532c7d750"><gtr:id>2ff6818641f1c9492b88729532c7d750</gtr:id><gtr:otherNames>Abdelgany A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1099-498X</gtr:issn><gtr:outcomeId>E25729B1491</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED321E8F-C635-4589-847A-19F19C817AEA</gtr:id><gtr:title>Selective cleavage of AChR cRNAs harbouring mutations underlying the slow channel myasthenic syndrome by hammerhead ribozymes.</gtr:title><gtr:parentPublicationTitle>Journal of RNAi and gene silencing : an international journal of RNA and gene targeting research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ff6818641f1c9492b88729532c7d750"><gtr:id>2ff6818641f1c9492b88729532c7d750</gtr:id><gtr:otherNames>Abdelgany A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1747-0854</gtr:issn><gtr:outcomeId>pm_13880_10_19771201</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C85CB22-F912-46B0-9511-58D385E77B09</gtr:id><gtr:title>Selective DNAzyme-mediated cleavage of AChR mutant transcripts by targeting the mutation site or through mismatches in the binding arm.</gtr:title><gtr:parentPublicationTitle>Journal of RNAi and gene silencing : an international journal of RNA and gene targeting research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ff6818641f1c9492b88729532c7d750"><gtr:id>2ff6818641f1c9492b88729532c7d750</gtr:id><gtr:otherNames>Abdelgany A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1747-0854</gtr:issn><gtr:outcomeId>pm_13880_10_19771202</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E25D9072-BEEA-4926-9864-795D1FF1EA4D</gtr:id><gtr:title>Dok-7 mutations underlie a neuromuscular junction synaptopathy.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a5861e43624583f637d02658bd01795"><gtr:id>9a5861e43624583f637d02658bd01795</gtr:id><gtr:otherNames>Beeson D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>CECC1D26FEB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>031194BE-91EB-46E4-875C-A3F71B721EDB</gtr:id><gtr:title>Phenotypical spectrum of DOK7 mutations in congenital myasthenic syndromes.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94720badb8d3af043a4399befc5bec26"><gtr:id>94720badb8d3af043a4399befc5bec26</gtr:id><gtr:otherNames>M?ller JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>63E3AC0EE78</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>16289820-C416-47D5-BF1C-E170830AC9EE</gtr:id><gtr:title>The congenital myasthenic syndromes.</gtr:title><gtr:parentPublicationTitle>Journal of neuroimmunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cad527b64016a7b9db06e95b702905ac"><gtr:id>cad527b64016a7b9db06e95b702905ac</gtr:id><gtr:otherNames>Palace J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0165-5728</gtr:issn><gtr:outcomeId>6ED5CFB0264</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E49EB678-5BFD-4E34-9D69-7D47B9BF2D41</gtr:id><gtr:title>The congenital myasthenic syndrome mutation RAPSN N88K derives from an ancient Indo-European founder.</gtr:title><gtr:parentPublicationTitle>Journal of medical genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94720badb8d3af043a4399befc5bec26"><gtr:id>94720badb8d3af043a4399befc5bec26</gtr:id><gtr:otherNames>M?ller JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0022-2593</gtr:issn><gtr:outcomeId>pm_13880_10_15286164</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54509C55-CB06-44A1-AC2A-7370F26B4142</gtr:id><gtr:title>Lack of association between acetylcholine receptor epsilon polymorphisms and early-onset myasthenia gravis.</gtr:title><gtr:parentPublicationTitle>Muscle &amp; nerve</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4000c007c9d100d1be674acab6b49bc"><gtr:id>f4000c007c9d100d1be674acab6b49bc</gtr:id><gtr:otherNames>Bonifati DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0148-639X</gtr:issn><gtr:outcomeId>pm_13880_10_14981744</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB8B2A72-C85F-45D8-B5FE-A162F701F45A</gtr:id><gtr:title>Preferential expression of AChR epsilon-subunit in thymomas from patients with myasthenia gravis.</gtr:title><gtr:parentPublicationTitle>Journal of neuroimmunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90286b447b7a319f1f89bb6184062100"><gtr:id>90286b447b7a319f1f89bb6184062100</gtr:id><gtr:otherNames>Maclennan CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0165-5728</gtr:issn><gtr:outcomeId>92A214A6503</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>36B6BAFF-1797-442B-9ACB-1D3058039CE8</gtr:id><gtr:title>Pre- and post-synaptic abnormalities associated with impaired neuromuscular transmission in a group of patients with 'limb-girdle myasthenia'.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/979674829fff6ccee05c039ee86c0144"><gtr:id>979674829fff6ccee05c039ee86c0144</gtr:id><gtr:otherNames>Slater CR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>C5599F6B727</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F661A301-211F-446C-88A9-AE185644B037</gtr:id><gtr:title>CHRND mutation causes a congenital myasthenic syndrome by impairing co-clustering of the acetylcholine receptor with rapsyn.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94720badb8d3af043a4399befc5bec26"><gtr:id>94720badb8d3af043a4399befc5bec26</gtr:id><gtr:otherNames>M?ller JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>F4303F5EE9C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>65903E7B-4D6C-42AC-BA7E-5DB89137F1DD</gtr:id><gtr:title>IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49a5a55005682573810740bce565abd5"><gtr:id>49a5a55005682573810740bce565abd5</gtr:id><gtr:otherNames>Leite MI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>1610D0F34B5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>829BE55F-6AB2-4E52-AF3A-F45C6CF68841</gtr:id><gtr:title>Diverse molecular mechanisms involved in AChR deficiency due to rapsyn mutations.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51cba051719f81ef2c20624dca20d9fa"><gtr:id>51cba051719f81ef2c20624dca20d9fa</gtr:id><gtr:otherNames>Cossins J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>06C3829D0CC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0151CAA-7185-4EF0-82FC-A8F3E96124B2</gtr:id><gtr:title>Myasthenia gravis seronegative for acetylcholine receptor antibodies.</gtr:title><gtr:parentPublicationTitle>Annals of the New York Academy of Sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/574f973bede4fd9f446edfa9f6f58020"><gtr:id>574f973bede4fd9f446edfa9f6f58020</gtr:id><gtr:otherNames>Vincent A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0077-8923</gtr:issn><gtr:outcomeId>B4B11594FB6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5913B45A-4783-463D-A696-C39EABC63F70</gtr:id><gtr:title>126th International Workshop: congenital myasthenic syndromes, 24-26 September 2004, Naarden, the Netherlands.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a5861e43624583f637d02658bd01795"><gtr:id>9a5861e43624583f637d02658bd01795</gtr:id><gtr:otherNames>Beeson D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>pm_13880_10_15951177</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>772A6E6D-8AC8-45F1-9EFB-B6165F5668E3</gtr:id><gtr:title>An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a23477857224cec7581b140a77ef79a3"><gtr:id>a23477857224cec7581b140a77ef79a3</gtr:id><gtr:otherNames>Giraud M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>EB5D20D84E4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69F660ED-E24D-4AB2-99D5-948DF50B290D</gtr:id><gtr:title>Detection and characterization of MuSK antibodies in seronegative myasthenia gravis.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ea44888afbe73899d254ed1d11c1315"><gtr:id>4ea44888afbe73899d254ed1d11c1315</gtr:id><gtr:otherNames>McConville J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>pm_13880_10_15048899</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE2B8027-36CD-4D7B-9F03-8A9CFE324A84</gtr:id><gtr:title>Congenital myasthenic syndromes and the formation of the neuromuscular junction.</gtr:title><gtr:parentPublicationTitle>Annals of the New York Academy of Sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a5861e43624583f637d02658bd01795"><gtr:id>9a5861e43624583f637d02658bd01795</gtr:id><gtr:otherNames>Beeson D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0077-8923</gtr:issn><gtr:outcomeId>804C6A701AF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DAF02DCC-0289-4FC4-915C-048C9320ECEF</gtr:id><gtr:title>Mutation history of the roma/gypsies.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ae788b4b878cf3b49bd5a12ae08b88d"><gtr:id>9ae788b4b878cf3b49bd5a12ae08b88d</gtr:id><gtr:otherNames>Morar B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>pm_13880_10_15322984</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B7E1E95-BEEB-4F31-891F-D23190FF0E49</gtr:id><gtr:title>Congenital myasthenic syndromes in childhood: diagnostic and management challenges.</gtr:title><gtr:parentPublicationTitle>Journal of neuroimmunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4345298aa80f7aab384e189cb31b897"><gtr:id>f4345298aa80f7aab384e189cb31b897</gtr:id><gtr:otherNames>Kinali M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0165-5728</gtr:issn><gtr:outcomeId>735C758F916</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D2E23F3A-9627-4CDE-8798-85FF3DA8EE24</gtr:id><gtr:title>Design of efficient DNAzymes against muscle AChR alpha-subunit cRNA in vitro and in HEK 293 cells.</gtr:title><gtr:parentPublicationTitle>Journal of RNAi and gene silencing : an international journal of RNA and gene targeting research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ff6818641f1c9492b88729532c7d750"><gtr:id>2ff6818641f1c9492b88729532c7d750</gtr:id><gtr:otherNames>Abdelgany A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1747-0854</gtr:issn><gtr:outcomeId>pm_13880_10_19771209</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>435521A1-D386-4835-94E8-735FC9D6E609</gtr:id><gtr:title>Distinct phenotypes of congenital acetylcholine receptor deficiency.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4825c06e28e3e36da21434ee220cd097"><gtr:id>4825c06e28e3e36da21434ee220cd097</gtr:id><gtr:otherNames>Burke G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>pm_13880_10_15145336</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>769391C0-C6F0-4CCD-A762-027491A62E46</gtr:id><gtr:title>Clinical Features and Diagnostic Usefulness of Antibodies to Clustered Acetylcholine Receptors in the Diagnosis of Seronegative Myasthenia Gravis.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa0b6ef76225dc642b86c7e03e3cfd59"><gtr:id>aa0b6ef76225dc642b86c7e03e3cfd59</gtr:id><gtr:otherNames>Rodr?guez Cruz PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>56dd5393195159.25398095</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01C76933-5E84-4F95-82BA-C0A195AAA039</gtr:id><gtr:title>Inhibition of acetylcholine receptor function by seronegative myasthenia gravis non-IgG factor correlates with desensitisation.</gtr:title><gtr:parentPublicationTitle>Journal of neuroimmunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1f21772285b10f0342006f38a0eb61d1"><gtr:id>1f21772285b10f0342006f38a0eb61d1</gtr:id><gtr:otherNames>Spreadbury I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0165-5728</gtr:issn><gtr:outcomeId>pm_13880_10_15833370</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>974B9916-7DC2-44BD-A3C3-BB31719567B1</gtr:id><gtr:title>Mutation analysis of CHRNA1, CHRNB1, CHRND, and RAPSN genes in multiple pterygium syndrome/fetal akinesia patients.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/285a802c943a5110f6b6faba4bfcd846"><gtr:id>285a802c943a5110f6b6faba4bfcd846</gtr:id><gtr:otherNames>Vogt J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>622AD53F371</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G117/490</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>149FA87E-B8CD-4FFC-B515-EAD312BED03B</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Musculoskeletal</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>